GT200600083A - Derivados de oxiindol - Google Patents
Derivados de oxiindolInfo
- Publication number
- GT200600083A GT200600083A GT200600083A GT200600083A GT200600083A GT 200600083 A GT200600083 A GT 200600083A GT 200600083 A GT200600083 A GT 200600083A GT 200600083 A GT200600083 A GT 200600083A GT 200600083 A GT200600083 A GT 200600083A
- Authority
- GT
- Guatemala
- Prior art keywords
- disease
- syndrome
- dyspepsia
- compounds
- oxyindol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
ESTA INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA (I) O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y SUS COMPUESTOS PARA EL TRATAMIENTO DE UNA AFECCIÓN MEDIADA POR LA ACTIVIDAD AGONISTA 5-HT4 TALES COMO, REFLUJO GASTROESOFÁGEO, ENFERMEDAD GASTROINTESTINAL, TRASTORNO DE MOTILIDAD GÁSTRICA, DISPEPSIA NO ULCEROSA, DISPEPSIA FUNCIONAL, SÍNDROME DEL INTESTINO IRRITABLE (IBS), ESTREÑIMIENTO, DISPEPSIA, ESOFAGITIS, ENFERMEDAD GASTROESOFÁGEA, NÁUSEAS, ENFERMEDAD DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDAD DE ALZHEIMER, TRASTORNO COGNITIVO, EMESIS, MIGRAÑA, ENFERMEDAD NEUROLÓGICA, DOLOR, TRASTORNOS CARDIOVASCULARES, INSUFICIENCIA CARDÍACA, ARRITMIA CARDIACA, DIABETES O SÍNDROME DE APNEA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65527605P | 2005-02-22 | 2005-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200600083A true GT200600083A (es) | 2006-11-07 |
Family
ID=36579484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200600083A GT200600083A (es) | 2005-02-22 | 2006-02-21 | Derivados de oxiindol |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7589109B2 (es) |
| EP (1) | EP1856110B1 (es) |
| JP (1) | JP4130220B1 (es) |
| KR (1) | KR100908547B1 (es) |
| CN (1) | CN101522668B (es) |
| AP (1) | AP2007004067A0 (es) |
| AR (1) | AR053548A1 (es) |
| AT (1) | ATE513827T1 (es) |
| AU (1) | AU2006217534B8 (es) |
| BR (1) | BRPI0607456A2 (es) |
| CA (1) | CA2598536C (es) |
| DK (1) | DK1856110T3 (es) |
| DO (1) | DOP2006000046A (es) |
| EA (1) | EA012615B1 (es) |
| ES (1) | ES2366375T3 (es) |
| GE (1) | GEP20094727B (es) |
| GT (1) | GT200600083A (es) |
| HK (1) | HK1135966A1 (es) |
| HN (1) | HN2006007884A (es) |
| IL (1) | IL184505A0 (es) |
| MA (1) | MA29260B1 (es) |
| MX (1) | MX2007010139A (es) |
| NL (1) | NL1031218C2 (es) |
| NO (1) | NO20073566L (es) |
| NZ (1) | NZ556627A (es) |
| PE (1) | PE20061096A1 (es) |
| TN (1) | TNSN07319A1 (es) |
| TW (1) | TW200640915A (es) |
| UA (1) | UA86301C2 (es) |
| UY (1) | UY29389A1 (es) |
| WO (1) | WO2006090279A1 (es) |
| ZA (1) | ZA200706420B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
| JP4130220B1 (ja) * | 2005-02-22 | 2008-08-06 | ファイザー株式会社 | ５ｈｔ４受容体アゴニストとしてのオキシインドール誘導体 |
| AU2006263564A1 (en) * | 2005-06-29 | 2007-01-04 | Merck Sharp & Dohme Corp. | 4-fluoro-piperidine T-type calcium channel antagonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| WO2007086559A1 (ja) * | 2006-01-27 | 2007-08-02 | Ube Industries, Ltd. | テトラヒドロピラン化合物の製造方法 |
| WO2008021422A2 (en) * | 2006-08-17 | 2008-02-21 | Wyeth | Process for the preparation of indolin-2-one derivatives useful as pr modulators |
| WO2009112874A1 (en) * | 2008-03-10 | 2009-09-17 | Eurodrug Laboratories B.V. | Modified release composition comprising doxofylline |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| MX2011008857A (es) * | 2009-02-27 | 2011-09-30 | Raqualia Pharma Inc | Derivados de oxiindol con actividad agonistica del receptor de motilina. |
| KR101544246B1 (ko) * | 2009-05-07 | 2015-08-12 | 유나이티드 세러퓨틱스 코오포레이션 | 프로스타시클린 유사체의 고체 제제 |
| EA020227B1 (ru) | 2009-09-14 | 2014-09-30 | Сувен Лайф Сайенсиз Лимитед | 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт |
| EP2533780B1 (en) | 2010-02-12 | 2017-08-23 | AskAt Inc. | 5-ht4 receptor agonists for the treatment of dementia |
| CN103380131B (zh) | 2011-09-19 | 2015-12-02 | 苏文生命科学有限公司 | 作为5-ht4受体配体的杂芳基化合物 |
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| WO2015123408A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為ｌｓｄ１抑制劑之環丙胺 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| JP6602778B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| EP3334709A1 (en) * | 2015-08-12 | 2018-06-20 | Incyte Corporation | Salts of an lsd1 inhibitor |
| JP7030720B2 (ja) * | 2016-02-16 | 2022-03-07 | ストロングブリッジ ダブリン リミテッド | 先端巨大症、先端巨大症がん、ｓｓｔ－ｒ５発現腫瘍、２型糖尿病、高血糖症、及びホルモン関連腫瘍の治療において使用するための、生理学的条件において難溶性であるベルドレオチド |
| WO2017184934A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN114105863B (zh) * | 2021-12-07 | 2023-11-28 | 江苏汉拓光学材料有限公司 | 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223511A (en) | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| US5552408A (en) | 1987-09-23 | 1996-09-03 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists |
| GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
| GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
| JPH06506443A (ja) | 1991-01-09 | 1994-07-21 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物 |
| US5955470A (en) | 1991-06-11 | 1999-09-21 | Merrell Pharmaceuticals, Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
| IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| GB9121170D0 (en) | 1991-10-05 | 1991-11-20 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9204565D0 (en) | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| US5280028A (en) | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
| US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| US5521193A (en) | 1992-06-24 | 1996-05-28 | G. D. Searle & Co. | Benzimidazole compounds |
| FR2694292B1 (fr) | 1992-07-29 | 1994-10-21 | Esteve Labor Dr | Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament. |
| KR950704328A (ko) | 1992-11-05 | 1995-11-17 | 데이비드 로버츠 | 5-HT₄ 수용체 길항제로서의 피페리딘 유도체(Piperidine Derivatives as 5-HT₄ Receptor Antagonists) |
| TW251287B (es) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
| GB9312348D0 (en) | 1993-06-16 | 1993-07-28 | Smithkline Beecham Plc | Pharmaceuticals |
| US5534521A (en) | 1993-06-23 | 1996-07-09 | G. D. Searle & Co. | Benzimidazole compounds |
| CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
| US5399562A (en) * | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
| GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| DE4440675A1 (de) | 1994-11-14 | 1996-05-15 | Basf Ag | Verfahren zur Herstellung von kautschukmodifizierten Formmassen mittels in den Kautschuk eingebauten, bei thermischer Zersetzung Radikale bildenden Gruppen |
| IT1275903B1 (it) | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| AU9309898A (en) | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
| US6069152A (en) | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6492375B2 (en) | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
| US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
| CA2348267A1 (en) | 1998-10-29 | 2000-05-11 | Henry H. Gu | Novel inhibitors of impdh enzyme |
| CA2397681C (en) | 1999-12-20 | 2011-03-15 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
| US20020128232A1 (en) | 2000-10-12 | 2002-09-12 | Henderson Scott A. | Heterocyclic angiogenesis inhibitors |
| EP1341773A2 (en) | 2000-12-07 | 2003-09-10 | Cv Therapeutics, Inc. | Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| DOP2003000703A (es) * | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| JP4671123B2 (ja) | 2003-06-23 | 2011-04-13 | 小野薬品工業株式会社 | 新規三環性複素環化合物 |
| ATE539077T1 (de) | 2003-09-03 | 2012-01-15 | Pfizer | Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| EP1758891A2 (en) * | 2004-06-15 | 2007-03-07 | Pfizer Japan Inc. | Benzimidazolone carboxylic acid derivatives |
| JP4130220B1 (ja) * | 2005-02-22 | 2008-08-06 | ファイザー株式会社 | ５ｈｔ４受容体アゴニストとしてのオキシインドール誘導体 |
-
2006
- 2006-02-10 JP JP2007556683A patent/JP4130220B1/ja not_active Expired - Fee Related
- 2006-02-10 CN CN200680005786XA patent/CN101522668B/zh not_active Expired - Fee Related
- 2006-02-10 KR KR1020077019124A patent/KR100908547B1/ko not_active IP Right Cessation
- 2006-02-10 ES ES06710525T patent/ES2366375T3/es active Active
- 2006-02-10 BR BRPI0607456-1A patent/BRPI0607456A2/pt not_active IP Right Cessation
- 2006-02-10 AP AP2007004067A patent/AP2007004067A0/xx unknown
- 2006-02-10 EP EP06710525A patent/EP1856110B1/en active Active
- 2006-02-10 DK DK06710525.4T patent/DK1856110T3/da active
- 2006-02-10 MX MX2007010139A patent/MX2007010139A/es active IP Right Grant
- 2006-02-10 AT AT06710525T patent/ATE513827T1/de not_active IP Right Cessation
- 2006-02-10 AU AU2006217534A patent/AU2006217534B8/en not_active Ceased
- 2006-02-10 NZ NZ556627A patent/NZ556627A/en not_active IP Right Cessation
- 2006-02-10 EA EA200701552A patent/EA012615B1/ru not_active IP Right Cessation
- 2006-02-10 CA CA2598536A patent/CA2598536C/en not_active Expired - Fee Related
- 2006-02-10 GE GEAP200610234A patent/GEP20094727B/en unknown
- 2006-02-10 WO PCT/IB2006/000519 patent/WO2006090279A1/en active Search and Examination
- 2006-02-20 PE PE2006000207A patent/PE20061096A1/es not_active Application Discontinuation
- 2006-02-20 AR ARP060100601A patent/AR053548A1/es unknown
- 2006-02-20 DO DO2006000046A patent/DOP2006000046A/es unknown
- 2006-02-21 GT GT200600083A patent/GT200600083A/es unknown
- 2006-02-21 HN HN2006007884A patent/HN2006007884A/es unknown
- 2006-02-21 TW TW095105776A patent/TW200640915A/zh unknown
- 2006-02-22 UY UY29389A patent/UY29389A1/es not_active Application Discontinuation
- 2006-02-22 NL NL1031218A patent/NL1031218C2/nl not_active IP Right Cessation
- 2006-02-22 US US11/360,095 patent/US7589109B2/en not_active Expired - Fee Related
- 2006-10-02 UA UAA200709522A patent/UA86301C2/uk unknown
-
2007
- 2007-07-09 IL IL184505A patent/IL184505A0/en unknown
- 2007-07-10 NO NO20073566A patent/NO20073566L/no not_active Application Discontinuation
- 2007-08-01 ZA ZA200706420A patent/ZA200706420B/xx unknown
- 2007-08-21 TN TNP2007000319A patent/TNSN07319A1/fr unknown
- 2007-08-22 MA MA30153A patent/MA29260B1/fr unknown
-
2009
- 2009-06-24 US US12/490,451 patent/US20100173925A1/en not_active Abandoned
-
2010
- 2010-01-06 HK HK10100064.9A patent/HK1135966A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200600083A (es) | Derivados de oxiindol | |
| UY28961A1 (es) | Derivados de ácido carboxílico de bencimidazolona antecedentes de la invención | |
| UY29421A1 (es) | Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones. | |
| US10300060B2 (en) | Trk-inhibiting compound | |
| UY28496A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| DE602006010563D1 (de) | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors | |
| EA201001585A1 (ru) | Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк) | |
| EA200701101A1 (ru) | Производные 3-фенилпиразола в качестве модуляторов 5-htсеротонинового рецептора, полезные для лечения расстройств, связанных с этим рецептором | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| WO2006041985A3 (en) | Thienopyridinone compounds and methods of treatment | |
| WO2016021742A1 (en) | Heterocyclic compounds as ep4 receptor antagonists | |
| EA201070916A1 (ru) | Двойные фармакофоры - pde4-мускариновые антагонисты | |
| EA201270217A1 (ru) | Замещенные бензамидные производные в качестве активаторов глюкокиназы (гк) | |
| PE20081664A1 (es) | Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica | |
| CU20070183A7 (es) | Derivados de oxindol | |
| DOP2005000113A (es) | Drivados de acido carboxilico de bencimidazolona | |
| TH76314A (th) | สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด |